Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab versus placebo after concurrent chemoradiation in limited-stage small-cell lung cancer
NL-OMON60144Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Durvalumab monotherapy, Durvalumab + tremelimumab and Placebo (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Apr 2019; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON60144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60144.